Pantheon Vision Reflects on a Year of Milestones and Sets Bold Goals for 2025

BALTIMORE--(BUSINESS WIRE)--Pantheon Vision, a pre-clinical stage medical device company developing bioengineered corneal implants to treat corneal blindness, is proud to celebrate a year of remarkable progress and set its sights on an even more ambitious 2025. Over the past year, Pantheon Vision has achieved significant milestones in its mission to transform corneal health and restore vision for patients worldwide. Highlights include:

• Technological advancements: Pantheon Vision made significant strides in refining and testing its proprietary corneal implant technology.
• Regulatory engagement: The Company conducted three meetings with the FDA, receiving valuable feedback to advance its regulatory pathway.
• Intellectual Property: Achieved milestones in establishing and protecting the company’s intellectual property
• Recognition: Pantheon Vision presented its bioengineered solution and path to success at several conferences and fundraising meetings.

“Looking back on the past year, I couldn’t be prouder of what our team has accomplished. From pushing the boundaries of innovation in ophthalmology to developing a solution that will truly make a difference in patients' lives, we’ve set a strong, promising foundation for the future,” said John Sheets, Jr., Ph.D., President & CEO, Pantheon Vision.

Looking Ahead to 2025: Growth and Momentum

As Pantheon Vision enters 2025, the company is poised to build on its momentum with several key initiatives:

• Advancing Fundraising Efforts: Pantheon Vision will focus on securing additional funding to accelerate product development and clinical research. Last spring they closed on a second tranche of funding, bringing the total to $4.3 million to date.
• Regulatory Check-in with the FDA: The team will meet with the FDA for a mid-development review, a critical step toward bringing its corneal implant to market.
• Presenting at Leading Conferences: Pantheon Vision is preparing to showcase its progress at upcoming ophthalmology conferences, including ARVO, ASCRS and AAO.
• Team Expansion: To support its ambitious goals, the company will expand its team, recruiting top talent across engineering, clinical, and regulatory disciplines.
• Key Partnerships: Pantheon Vision has been closely working with a manufacturer to develop its bioengineered corneal implant.

Sheets continues, “As we enter 2025, I’m filled with excitement for the opportunities ahead. This year promises to be even more transformative as we continue to advance our mission, meet critical milestones, build a world-class team, and deliver results for stakeholders and those suffering from corneal disease and blindness. We are excited to share our journey with patients, partners, and the broader ophthalmology community.”

About Pantheon Vision

Pantheon Vision is a pre-clinical stage medical device company developing bioengineered corneal implants to improve corneal procedures and reduce the reliance on donor tissue to address corneal blindness in emerging and developed markets. For more information, please visit pantheonvision.com or visit us on LinkedIn.